Inclusion Criteria:

- Histologically proven non-small cell lung cancer

- Presence of measurable disease by RECIST

- Inoperable Stage IIIA or IIIB, proven by CT or MRI (except wet T4). However, N2 or
N3 should be confirmed by PET or pathology. (For T4, PET is optional)

- 18 years of age or older

- ECOG Performance status 0-1

- No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy

- Serum Hgb ≥ 10 gm/dL, platelet ≥ 100,000/μL, absolute neutrophil count ≥ 1,500/μL

- Serum creatinine ≤1.25 x UNL or creatinine clearance ≥60 mlmL/min

- Serum bilirubin ≤ 1.5 x UNL, AST (SGOT) and ALT (SGPT) ≤ 2.5 x UNL, alkaline
phosphatase ≤ 5 x UNL

- FEV1> 0.8 L

- Patients must sign an informed consent

Exclusion Criteria:

- Carcinoid tumor, small cell carcinoma of lung

- Patients with any distant metastasis

- History of another malignancy within the last five years except cured basal cell
carcinoma of skin and cured carcinoma in-situ of uterine cervix

- Any other morbidity or situation with contraindication for chemotherapy (e.g. active
infection, myocardial infarction preceding 6 months, symptomatic heart disease
including unstable angina, congestive heart failure or uncontrolled arrhythmias,
immunosuppressive treatment)

- Pregnant or lactating women, women who has not taken test of pregnancy (within 14
days before the first administration) and pregnant women

- Women and men of childbearing potential who have no willing of employing adequate
contraception